The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies (colloquially referred to as cancer vaccines). This is an important step in bringing these promising therapies closer to clinical practice…
…Julian Beach, MHRA Executive Director of Healthcare Quality and Access said:
“Individualised cancer immunotherapies, while still being tested in clinical trials, are a very exciting development in our hunt to find new and better ways to treat cancer, which is a leading cause of death worldwide.
“Because these treatments are tailored to an individual’s tumour, they pose unique scientific questions on how they should be regulated.”
Market Data 
Markets 
AI
